Orchid Pharma Limited has announced the schedule for its analysts and investors earnings call to discuss the financial performance for the fourth quarter and financial year ended March 31, 2026. The conference is set to take place on Tuesday, May 26, 2026, at 4:30 PM IST. The session is being hosted by Systematix Institutional Equities.

Management Participation

The company's management team will be represented by key executives during the call. The participants include Mr. Manish Dhanuka, Managing Director; Mr. Mridul Dhanuka, Whole Time Director; and Mr. Sunil Kumar Gupta, Chief Financial Officer. They will address the financial results and answer queries from analysts and investors.

Dial-in Details

Participants can join the conference call using the dial-in numbers provided below. A Diamond Pass service is also available for connection without operator assistance.

Additional Information

The information regarding the earnings call will be hosted on the company's official website. The schedule is subject to change due to exigencies, and any modifications will be communicated accordingly. Investors can contact Systematix Institutional Equities for further details regarding the event.

Orchid pharma has received a favorable ruling from the National Company Law Tribunal (NCLT) Chennai Bench, which dismissed an application filed by DBS Bank regarding lease rent claims during the Corporate Insolvency Resolution Process (CIRP) period. The order was pronounced on April 02, 2026, and made available on the NCLT website on April 10, 2026.

NCLT Order Details

The NCLT Chennai Bench, presided over by Hon'ble Member (Judicial) Shri. Jyoti Kumar Tripathi and Hon'ble Member (Technical) Shri. Ravichandran Ramasamy, dismissed the Interim Application filed by DBS Bank (formerly known as Lakshmi Villas Bank). The application sought relief under multiple sections of the Insolvency and Bankruptcy Code, 2016.

Nature of DBS Bank's Application

DBS Bank (erstwhile Lakshmi Vilas Bank) had filed an Interim Application claiming lease dues for the CIRP period and Insolvency Resolution Process Cost. The bank sought relief under Section 60(5)(a), (b) and (c) read with Sections 30(2) and 53 of the Insolvency and Bankruptcy Code, 2016, along with various regulations under the IBBI (Insolvency Resolution Process for Corporate Persons) Regulations, 2016.

Financial Impact Assessment

Orchid Pharma has disclosed that the NCLT's dismissal of DBS Bank's application has no quantifiable financial impact on the company's operations or other activities. This outcome represents a positive development for the pharmaceutical company, as it eliminates potential financial obligations that could have arisen from the lease rent claims.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This intimation follows an earlier communication dated September 27, 2023, indicating that the legal proceedings have been ongoing for a considerable period.

Court Proceedings

The hearing was conducted through video conferencing on April 02, 2026, at 10:30 AM. The respondent was represented by learned counsel Mr. Kastubh Prakash during the proceedings. The tribunal's decision to dismiss the application marks the conclusion of this particular legal matter in favor of Orchid Pharma.